Syntrix Pharmaceuticals employs a diverse and flexible approach to drug development, emphasizing a "technology agnostic" philosophy. This means that the company does not confine itself to a specific type of therapeutic technology but instead focuses on addressing significant medical needs with the potential for breakthrough therapies. Their research spans various clinical areas, particularly pain, oncology, and autoimmunity, and they utilize both small molecules and biologics, such as proteins and antibodies, to tackle these challenges. The company’s commitment to innovation is reflected in their ability to create new therapeutic candidates from the ground up, as seen with their clinical development of small molecules like SX-682 and desmetramadol.

Collaboration is a cornerstone of Syntrix's research strategy, as they actively engage with a wide array of talented individuals and organizations globally. This collaborative model allows them to leverage expertise from both internal teams and external partners, including academic researchers and innovative research organizations. The inspiration for their research can stem from personal experiences of their scientists or from significant findings in the scientific literature. By fostering an entrepreneurial spirit among their researchers, Syntrix encourages exploration of new research avenues, which, when combined with intellectual property and business strategy, leads to the development of high-value medicines that can significantly impact patient care.

United States

Syntrix has pioneered the development of new therapies for over 10 years. As a clinical-stage company, we are tackling some of medicine’s most high-value diseases.  One thing has remained unchanged however, our shared commitment to improving the lives of patients.

Syntrix Pharmaceuticals

Company Details